Genetics: Predictive value of KRAS mutations in chemoresistant CRC

Nature Reviews Clinical Oncology

Volumn 6, Issue 6, 2009, Pages 306-307

  Lièvre, Astrid ^b   Laurent Puig, Pierre ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONSERVATIVE TREATMENT; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; GENE FUNCTION; GENE MUTATION; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SURVIVAL TIME; TREATMENT RESPONSE; WILD TYPE; COLORECTAL TUMOR; DRUG RESISTANCE; GENETICS; MUTATION; NOTE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 68549121184     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.69     Document Type: Article

References (10)

1. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
2. Saltz, L. B. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201-1208 (2004).
3. Jonker, D. J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040-2048 (2007).
4. De Roock, W. et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19, 508-515 (2008).
5. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
6. Amado, R. G. et al. wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
7. Bokemeyer, C. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663-671 (2009).
8. van Cutsem, E. et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [Abstract]. Proc. Am. Soc. Clin. Oncol. 26, 2 (2008).
9. Etienne-Grimaldi, M. C. et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin. Cancer Res. 14, 4830-4835 (2008).
10. Di Nicolantonio, F. et al. wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712 (2008).